

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/114501 A1

(51) International Patent Classification:

<i>C07K 14/575</i> (2006.01)	<i>A61P 3/10</i> (2006.01)
<i>A61K 38/00</i> (2006.01)	<i>A61P 43/00</i> (2006.01)
<i>A61K 38/08</i> (2019.01)	<i>C07D 401/12</i> (2006.01)
<i>A61K 38/16</i> (2006.01)	<i>C07D 401/14</i> (2006.01)
<i>A61K 38/26</i> (2006.01)	<i>C07D 471/04</i> (2006.01)
<i>A61P 1/04</i> (2006.01)	<i>C07K 7/06</i> (2006.01)
<i>A61P 1/16</i> (2006.01)	<i>C07K 7/08</i> (2006.01)
<i>A61P 3/00</i> (2006.01)	<i>C07K 14/585</i> (2006.01)
<i>A61P 3/04</i> (2006.01)	<i>C07K 14/605</i> (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2024/084031

(22) International Filing Date:

29 November 2024 (29.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23213366.0 30 November 2023 (30.11.2023) EP

(71) Applicant: **NOVO NORDISK A/S** [DK/DK]; Novo Alle 1, 2880 Bagsværd (DK).

(72) Inventors: **KRUSE, Thomas**; Novo Alle 1, 2880 Bagsværd (DK). **LAU, Jesper F.**; Novo Alle 1, 2880 Bagsværd (DK). **FRICH, Camilla Kaas**; Novo Alle 1, 2880 Bagsværd (DK). **MADSEN, Charlotte Stahl**; Novo Alle 1, 2880 Bagsværd (DK). **HAXVIG, Christina Sophie**; Novo Alle 1, 2880 Bagsværd (DK). **BEHRENS, Carsten**; Novo Alle 1, 2880 Bagsværd (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: TRI-AGONISTS OF THE GLP-I, GIP, AND AMYLIN RECEPTORS

(57) Abstract: The present invention relates to a GLP-I-/GIP-/amylin-receptor tri-agonist. This GLP-I-/GIP-/amylin-receptor tri-agonist may have improved pharmacokinetic properties and may be suitable for once weekly administration. The invention also relates to pharmaceutical compositions comprising such a GLP-I-/GIP-/amylin-receptor tri-agonist. The tri-agonist and pharmaceutical compositions comprising it may be used as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

WO 2025/114501 A1